Molecular diagnostics developer PreludeDx has finalized a $20 million funding round. The company will use the funds to further develop a risk assessment tool for women with ductal carcinoma in situ (DCIS).
The financing round was led by Evidity Health Capital and included participation from new and existing investors, according to PreludeDx. In addition, Evidity Health Capital Managing Director Alejandro Sanchez will join PreludeDx's board of directors.
PreludeDx said it would use the funds to support the commercial expansion of its DCISionRT risk assessment test for women with DCIS and to continue development of its radiogenomics platform for early-stage breast cancer and other cancers.